@article{HeinrichNandaRehnetal.2013,
  author    = {Heinrich, T. and Nanda, I. and Rehn, M. and Zollner, U. and Frieauff, E. and Wirbelauer, J. and Grimm, T. and Schmid, M.},
  title     = {Live-Born Trisomy 22: Patient Report and Review},
  series = {Molecular Syndromology},
  volume    = {3},
  journal   = {Molecular Syndromology},
  number    = {6},
  issn      = {1661-8769},
  doi       = {10.1159/000346189},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196535},
  pages     = {262-269},
  year      = {2013},
  abstract  = {Trisomy 22 is a common trisomy in spontaneous abortions. In contrast, live-born trisomy 22 is rarely seen due to severe organ malformations associated with this condition. Here, we report on a male infant with complete, non-mosaic trisomy 22 born at 35 + 5 weeks via caesarean section. Peripheral blood lymphocytes and fibroblasts showed an additional chromosome 22 in all metaphases analyzed (47,XY,+22). In addition, array CGH confirmed complete trisomy 22. The patient's clinical features included dolichocephalus, hypertelorism, flattened nasal bridge, dysplastic ears with preauricular sinuses and tags, medial cleft palate, anal atresia, and coronary hypospadias with scrotum bipartitum. Essential treatment was implemented in close coordination with the parents. The child died 29 days after birth due to respiratory insufficiency and deterioration of renal function. Our patient's history complements other reports illustrating that children with complete trisomy 22 may survive until birth and beyond.},
  language  = {en}
}
@article{WirbelauerHofHacker1988,
  author    = {Wirbelauer, J. and Hof, H. and Hacker, J{\"o}rg},
  title     = {Die Wirkung von Desacetylcefotaxin, einem Metaboliten von Cefotaxim, in vitro und auf die experimentelle Infektion mit Escherichia coli},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-40348},
  year      = {1988},
  abstract  = {Die MHK-Werte von Desacetylcefotaxim gegen verschiedene, z. T. ampicillinresistente St{\"a}mme von Escherichia coH, die mit Hilfe einer Agardilutionsmethode erhoben wurden, waren h{\"o}her als die von Cefotaxim und Ceftriaxon, jedoch niedriger als die von Cefoxitin. In einem Modell der systemischen Infektion der Maus mit einem plasmidtragenden, betalactamaseproduzierenden Stamm von E. coli f{\"u}hrte die Therapie mit Desacetylcefotaxim zu einer starken Reduktion der Keime pro Leber. Im Vergleich zur Therapie mit Cefotaxim trat die protektive Wirkung aber verlangsamt ein. Desacetylcefotaxim ist also kein unn{\"u}tzes Abbauprodukt von Cefotaxim.},
  language  = {de}
}